MARKET

ALKS

ALKS

Alkermes
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.03
-0.42
-2.28%
After Hours: 18.03 0 0.00% 16:28 09/18 EDT
OPEN
18.72
PREV CLOSE
18.45
HIGH
19.04
LOW
17.45
VOLUME
4.05M
TURNOVER
--
52 WEEK HIGH
21.93
52 WEEK LOW
11.98
MARKET CAP
2.87B
P/E (TTM)
-22.5347
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile

Analyst Price Target

The average ALKS stock price target is 19.73 with a high estimate of 26.00 and a low estimate of 15.00.

Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ALKS
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Alkermes Plc stock information, including NASDAQ:ALKS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALKS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALKS stock methods without spending real money on the virtual paper trading platform.